Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyobacteriophage is a polyvalent bacteriophage preparation composed of a sterile mixture of phage filtrates that specifically target and lyse several common pyogenic (pus-forming) bacteria. Developed and manufactured primarily by **Microgen** in Russia, this cocktail is designed to treat various inflammatory and purulent infections, including those of the respiratory tract, urinary system, and skin. Its therapeutic action relies on the lytic cycle of bacteriophages: the viruses attach to specific receptors on the bacterial cell wall, inject their genetic material, and hijack the cellular machinery to produce new phage particles, ultimately causing the bacterial cell to burst (lysis). This targeted approach allows for the treatment of infections, including those caused by multidrug-resistant (MDR) strains, while minimizing impact on the natural human microbiota.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pyobacteriophage.